The fact that a homozygous Ptch mutation in isolated K5+ epidermal cells is not sufficient for BCC development also questions the current BCC therapy based on Hh signaling inhibitors (e.g., vismodegib). The gene discussed is PTCH1; the disease is skin basal cell carcinoma.